1. Striatal Glutathione in First-episode Psychosis Patients Measured In Vivo with Proton Magnetic Resonance Spectroscopy
- Author
-
Pablo León-Ortiz, Xiangling Mao, Francisco Reyes-Madrigal, Ricardo Mora-Durán, Camilo de la Fuente-Sandoval, and Dikoma C. Shungu
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Psychosis ,Antioxidant ,medicine.medical_treatment ,Proton Magnetic Resonance Spectroscopy ,medicine.disease_cause ,03 medical and health sciences ,chemistry.chemical_compound ,Young Adult ,0302 clinical medicine ,In vivo ,Internal medicine ,medicine ,Humans ,First episode ,business.industry ,General Medicine ,Glutathione ,medicine.disease ,Proton magnetic resonance ,030104 developmental biology ,Endocrinology ,chemistry ,Psychotic Disorders ,Schizophrenia ,030220 oncology & carcinogenesis ,Female ,business ,Oxidative stress - Abstract
Deficits of brain glutathione (GSH), the most abundant and primary antioxidant in living tissue, and associated redox imbalance are postulated to be implicated in schizophrenia. This pilot clinical study compared the levels of striatal GSH, measured in vivo with proton magnetic resonance spectroscopy (1H MRS) at 3T, in 10 drug-naive, first-episode psychosis (FEP) patients with those in 9 matched healthy control subjects. The results revealed a significant GSH deficit in FEP patients (0.92 ± 0.24 × 10-3) compared to the healthy control group (1.10 ± 0.10 × 10-3) (U = 25.00, p = 0.02), as well as a positive correlation between GSH levels and the Positive Symptoms subscale of the PANSS in the FEP group (ρ = 0.96; p
- Published
- 2019